Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience WARRINGTON, Pa., Feb. 4, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today […]
Financial
Mentice publishes the company’s year-end report for the period January-December 2020
STOCKHOLM, Feb. 4, 2021 /PRNewswire/ — Strong order intake and substantial improvement of the company’s order book as well as operating cash flowFourth quarter (October-December 2020) Order intake amounted to 73.1 (54.7) MSEK. Net sales amounted to 45.9 (60.2) MSEK. Operating income for the period before depreciations (EBITDA) totalled 4.3 (11.8) MSEK. Net […]
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing […]
Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data
Allschwil, Switzerland – February 4, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020. Business highlights Positive results in the Phase 3 program of daridorexant, demonstrating improved overall sleep and daytime functioning of patients with insomnia Daridorexant new drug application (NDA) submitted to the […]
Cardiovascular Systems, Inc. Reports Fiscal 2021 Second-quarter Financial Results
Conference Call Scheduled for Today, February 3, 2021, at 3:30 PM CT (4:30 PM ET) Revenues of $64.2 million increased 6% sequentially compared to first quarter Net loss was $0.1 million, or $0.00 per basic and diluted share Management provides fiscal 2021 third quarter revenue guidance of $60 million to […]
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
Reports Fourth Quarter Revenues of $11.1 Billion; Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46; Full-Year Loss Per Share of $3.99 and Non-GAAP EPS of $6.44 Completes Acquisition of MyoKardia, Expanding Leading Cardiovascular Franchise Announces Debt Tender Offer for an […]
Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, […]
Quanterix Prices Public Offering of Common Stock
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock at a public offering price of $70.00 per share. All of the shares in […]
Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
– Acceleron expects to report approximately $23.0 million in royalty revenue for Q4 2020 from approximately $115 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – – Acceleron expects to report approximately $54.8 million in royalty revenue for full year 2020 from approximately $274 million in […]
Boston Scientific Announces Results For Fourth Quarter And Full Year 2020
MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational1 basis and (8.0) percent on an organic2 basis, all compared to the prior year period. Included […]
Recent
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Popular
- No commented posts yet